Cyclic nucleotide phosphodiesterases.

@article{Essayan2001CyclicNP,
  title={Cyclic nucleotide phosphodiesterases.},
  author={David M. Essayan},
  journal={The Journal of allergy and clinical immunology},
  year={2001},
  volume={108 5},
  pages={
          671-80
        }
}
  • D. Essayan
  • Published 1 November 2001
  • Biology
  • The Journal of allergy and clinical immunology
Cyclic nucleotide second messengers (cAMP and cGMP) play a central role in signal transduction and regulation of physiologic responses. Their intracellular levels are controlled by the complex superfamily of cyclic nucleotide phosphodiesterase (PDE) enzymes. Continuing advances in our understanding of the molecular pharmacology of these enzymes has led to the development of selective inhibitors as therapeutic agents for disease states ranging from cancer and heart failure to depression and… 
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
TLDR
Basic biochemical properties, cellular regulation, expression patterns, and physiological functions of the different PDE isoforms will be discussed and how these properties relate to the current and future development of PDE inhibitors as pharmacological agents is especially considered.
Cyclic nucleotide phosphodiesterase families in intracellular signaling and diabetes.
  • C. Lugnier
  • Biology
    Advances in experimental medicine and biology
  • 2001
TLDR
The altered PDE family may represent new classes of drug targets for diabetes since it was reported that insulin-induced phosphorylation activates PDE3 and that PDE4 inhibitors may prevent installation of diabetes (Liang et al., 1998).
Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.
TLDR
This review summarizes the expression and function of PDEs in normal haematopoietic cells and the evidence that family-specific inhibitors will be therapeutically useful in myeloid and lymphoid malignancies.
Phosphodiesterase 5 mechanisms and therapeutic applications.
  • A. Burnett
  • Biology
    The American journal of cardiology
  • 2005
Type 5 phosphodiesterase inhibition: the focus shifts to the heart.
TLDR
Load-independent measures of contractility are used to assess the myocardial effects of an agent (sildenafil) that increases intracellular cGMP levels by inhibiting its degradation.
PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.
TLDR
PDE4 enzymes stand at a crossroads that allows them to integrate various signalling pathways with that of cAMP in spatially distinct compartments, and the recent elucidation of the structure of the PDE4 catalytic unit allows for molecular insight into the mode of catalysis as well as substrate and inhibitor selectivity.
Assay and purification of calmodulin-dependent cyclic nucleotide phosphodiesterase and isozyme separation.
TLDR
This work has shown that the CaM-dependent cyclic nucleotide phosphodiesterase (CaMPDE) is one of the most intensively studied and best characterized PDEs.
EFFECT OF PHOSPHODIESTERASE 4 (PDE4) INHIBITORS ON EOTAXIN EXPRESSION IN HUMAN BRONCHIAL EPITHELIAL CELLS
TLDR
PDE4 inhibitors increase cyclic adenosine monophosphate level in cells and inhibit various stages of the inflammatory process, and eotaxins are the strongest chemotactic agents for eosinophils.
...
...

References

SHOWING 1-10 OF 133 REFERENCES
Cyclic nucleotide phosphodiesterases: relating structure and function.
Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action.
TLDR
This review summarizes many studies that have contributed significantly to an improved understanding of the catalytic, regulatory, and structural properties of these protein kinases and provides insights into the mechanisms by which these enzymes produce their specific physiological effects.
The molecular biology of cyclic nucleotide phosphodiesterases.
  • M. Conti, S. C. Jin
  • Biology
    Progress in nucleic acid research and molecular biology
  • 1999
Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity.
TLDR
The three-dimensional structure of the catalytic domain of phosphodiesterase 4B2B to 1.77 angstrom resolution suggests the mechanism of action and basis for specificity and will provide a framework for structure-assisted drug design for members of the phosphodiedterase family.
Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells.
Analysis of cyclic nucleotide phosphodiesterase (PDE) activity in cellular fractions from cultured rat pheochromocytoma (PC12) cells has shown that the predominant hydrolytic activity in both
Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase.
TLDR
Cl cloning and characterization of a novel cAMP-specific PDE from mouse testis shows that PDE8 is expressed in the seminiferous epithelium in a stage-specific manner, and clearly represents a previously unknown PDE gene family designated as Pde8.
Structure, Mechanism, and Regulation of Mammalian Adenylyl Cyclase*
  • J. Hurley
  • Biology, Chemistry
    The Journal of Biological Chemistry
  • 1999
TLDR
The essentials of catalysis are described and then how these elements are controlled by each of the major regulators are considered: free metal ions, P-site inhibitors, forskolin, G-proteins, Ca/calmodulin, and protein phosphorylation.
...
...